IC
JAZZ icon

Inscription Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Inscription Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$237K Buy
1,253
+30
+2% +$5.24K 0.02% 560
2025
Q4 		$208K Buy
+1,223
New +$187K 0.02% 604
2019
Q2 		– Sell
-142
Closed -$20K – 182
2019
Q1 		$20K Sell
142
-310
-69% -$40.4K 0.01% 221
2018
Q4 		$56K Buy
+452
New +$67.1K 0.03% 190

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Inscription Capital's JAZZ Position: Q1 2026 in Review

Inscription Capital increased its Jazz Pharmaceuticals (JAZZ) stake by 2.5% in Q1 2026, buying an estimated $5.24K and bringing the position to 1,253 shares worth $237K. The position accounts for 0.02% of the portfolio, ranked #560.

Inscription Capital first reported a position in JAZZ in Q4 2018 and has held it in 4 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Inscription Capital held 1,253 shares of Jazz Pharmaceuticals worth $237K as of Q1 2026.
  • Inscription Capital bought 30 Jazz Pharmaceuticals shares in Q1 2026, an estimated $5.24K.
  • Jazz Pharmaceuticals made up 0.02% of Inscription Capital's portfolio in Q1 2026, its #560 holding.
  • Inscription Capital first reported a position in Jazz Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Inscription Capital's 13F filing for Q1 2026, filed 20 Apr 2026.